SEOM‑GEICO Clinical Guidelines on cervical cancer (2023)

• Luis Manso ^[7] ; Avinash Ramchandani Vaswani ^[1] ; Ignacio Romero ^[2] ; Luisa Sánchez Lorenzo ^[3] ; María José Bermejo Pérez ^[8] ; Purificación Estévez García ^[9] ; Lorena Fariña Madrid ^[10] ; Yolanda García García ^[4] ; Marta Gil Martin ^[5] ; María Quindós ^[6]
  1. [1] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  2. [2] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  3. [3] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  4. [4] Universitat Autònoma de Barcelona

     Universitat Autònoma de Barcelona

     Barcelona, España

     
  5. [5] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  6. [6] Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia

     Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia

     Valencia, España

     
  7. [7] Medical Oncology Department, Hospital Univ. 12 de Octubre, Madrid, Spain
  8. [8] Medical Oncology Department, UGCI Oncol. Hosp Univer Regional y Virgen Victoria, IBIMA, Málaga, Spain
  9. [9] Medical Oncology Department, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Seville, Spain
  10. [10] Medical Oncology Department, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2771-2782
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in frst line and as monotherapy in second line after platinum-based chemotherapy, has signifcantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.